Search

Your search keyword '"J.H.A.M. Kaanders"' showing total 60 results
Start Over Author "J.H.A.M. Kaanders"
60 results on '"J.H.A.M. Kaanders"'

1. Radiotherapy induces an increase in serum antioxidant capacity reflecting tumor response

Author

F.V. Naumann, J.H.A.M. Kaanders, W.J.M. Peeters, G.J. Adema, F.C.G.J. Sweep, J. Bussink, and P.N. Span

Subjects
Squamous cell carcinoma of head and neck, Reactive oxygen species, NF-E2-related factor 2 (NRF2), Antioxidants, Head and neck cancers, Oxidative stress, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background and purpose: Radiotherapy (RT) is a mainstay component of treatment for patients with head and neck squamous cell carcinoma (HNSCC), but responses vary. As RT relies upon oxidative damage, antioxidant expression in response to RT-induced reactive oxygen species (ROS) could compromise treatment response. We aimed to examine local and systemic antioxidant responses to increased RT-induced ROS in relation to treatment success. Materials and methods: Nuclear factor erythroid 2-related factor 2 (NRF2), the main antioxidant transcription factor, was immunofluorescently stained in FaDu cells and in tumor biopsies of patients with oral cavity/oropharynx HNSCC before and after five fractions of RT. Besides, total antioxidant capacity (TAC) was analyzed in HNSCC tumor cells in vitro and in serum of HNSCC patients before, during, and after RT. Results: Data revealed an increase in NRF2 expression and TAC in head and neck cancer cells in vitro over the course of 5 daily fractions of 2 Gy. In accordance, also in patients’ tumors NRF2 expression increased, which was associated with increased serum TAC during RT. Increasing serum TAC was related to impaired local tumor control. Conclusion: Radiation induced NRF2 expression and upregulated TAC, which may compromise the effect of RT-induced ROS. Changes in serum TAC during RT could serve as a novel predictor of treatment outcome in HNSCC patients.Medical Ethics Review Committee (CMO) approval – CMO number: 2007/104.

Published
2024
Full Text
View/download PDF

2. Personalized neck irradiation guided by sentinel lymph node biopsy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx with a clinically negative neck: (Chemo)radiotherapy to the PRIMary tumor only. Protocol of the PRIMO study

Author

S. van den Bosch, R.P. Takes, M. de Ridder, R. de Bree, A. Al-Mamgani, W.H. Schreuder, F.J.P. Hoebers, S. van Weert, J.B.W. Elbers, J.A. Hardillo, T.W.H. Meijer, B.E.C. Plaat, M.A. de Jong, J.C. Jansen, D.J. Wellenstein, G.B. van den Broek, W.V. Vogel, A.I.J. Arens, and J.H.A.M. Kaanders

Subjects
Head and neck cancer, Sentinel lymph node biopsy, Elective neck irradiation, Radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Elective neck irradiation (ENI) is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques. It is conceivable that personalized neck irradiation can be performed guided by the results of sentinel lymph node biopsy (SLNB). It is expected that ENI can be omitted to one or both sides of the neck in 9 out of 10 patients, resulting in less radiation side effects with better quality of life. Methods/design: This is a multicenter randomized controlled trial aiming to compare safety and efficacy of treatment with SLNB guided neck irradiation versus standard bilateral ENI in 242 patients with cN0 squamous cell carcinoma of the oropharynx, larynx or hypopharynx for whom bilateral ENI is indicated. Patients randomized to the experimental-arm will undergo SLNB. Based on the histopathologic status of the SLNs, patients will receive no ENI (if all SLNs are negative), unilateral neck irradiation only (if a SLN is positive at one side of the neck) or bilateral neck irradiation (if SLNs are positive at both sides of the neck). Patients randomized to the control arm will not undergo SLNB but will receive standard bilateral ENI. The primary safety endpoint is the number of patients with recurrence in regional lymph nodes within 2 years after treatment. The primary efficacy endpoint is patient reported xerostomia-related quality of life at 6 months after treatment. Discussion: If this trial demonstrates that the experimental treatment is non-inferior to the standard treatment in terms of regional recurrence and is superior in terms of xerostomia-related quality of life, this will become the new standard of care.

Published
2024
Full Text
View/download PDF

3. Considerations for radiotherapy in Bloom Syndrome

Author

M.E.L. van der Burg, C.J. Dommering, J.H.A.M. Kaanders, I. Pico, M. van Deuren, M.H.D. Schoenaker, Stefanie S. V. Henriet, Corry M.R. Weemaes, W.V. Vogel, Sanami Takada, Michèl A.A.P. Willemsen, Human genetics, and CCA - Cancer biology and immunology

Subjects
Adult, Male, DNA repair, medicine.medical_treatment, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Radiation Tolerance, All institutes and research themes of the Radboud University Medical Center, Genetics, medicine, Humans, Bloom syndrome, DNA Breaks, Double-Stranded, Radiosensitivity, Genetics (clinical), Immunodeficiency, Cells, Cultured, Chemotherapy, Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7], RecQ Helicases, Radiotherapy, Toxicity, business.industry, Carcinoma, General Medicine, Fibroblasts, Middle Aged, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], medicine.disease, Radiation therapy, Ataxia-telangiectasia, Chromosomal instability disorder, Cancer research, Female, business, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Bloom Syndrome (BS) is a genetic DNA repair disorder, caused by mutations in the BLM gene. The clinical phenotype includes growth retardation, immunodeficiency and a strong predisposition to different types of malignancies. Treatment of malignancies in BS patients with radiotherapy or chemotherapy is believed to be associated with increased toxicity, but clinical and laboratory data are lacking. We collected clinical data of two Dutch BS patients with solid tumors. Both were treated with radiotherapy before the diagnosis BS was made and tolerated this treatment well. In addition, we collected fibroblasts from BS patients to perform in vitro clonogenic survival assays to determine radiosensitivity. BS fibroblasts showed less radiosensitivity than the severely radiosensitive Artemis fibroblasts. Moreover, studies of double strand break kinetics by counting 53BP1 foci after irradiation showed similar patterns compared to healthy controls. In combination, the clinical cases and laboratory experiments are valuable information in the discussion whether radiotherapy is absolutely contraindicated in BS, which is the Case in other DNA repair syndromes like Ataxia Telangiectasia and Artemis.

Published
2021
Full Text
View/download PDF

4. PH-0382 Radiotherapy as nose preservation treatment for cancer of the nasal vestibule: the Dutch experience

Author

Cornelia G. Verhoef, Johannes A. Langendijk, M. R. Vergeer, Frederik W.R. Wesseling, J.H.A.M. Kaanders, Ellen M. Zwijnenburg, Michal D. Czerwinski, Peter P. Jansen, and Abrahim Al-Mamgani

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Hematology, medicine.disease, Surgery, Radiation therapy, medicine.anatomical_structure, Oncology, medicine, Radiology, Nuclear Medicine and imaging, Nasal vestibule, business, Nose
Published
2021
Full Text
View/download PDF

5. PH-0052 Do head and neck cancer patients in randomized trials represent the population in daily practice?

Author

S. Van den Bosch, J.H.A.M. Kaanders, and Jos Kleijnen

Subjects
medicine.medical_specialty, education.field_of_study, business.industry, Population, Head and neck cancer, Hematology, medicine.disease, law.invention, Oncology, Randomized controlled trial, law, Daily practice, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, education, business
Published
2021
Full Text
View/download PDF

6. SP-0625: Merkel cell carcinoma: an oncologic emergency

Author

Gosse J. Adema, Ellen M. Zwijnenburg, R.P. Takes, Willem L. J. Weijs, C.M.L. van Herpen, S.F.K. Lubeek, J.H.A.M. Kaanders, and J.E.M. Werner

Subjects
Oncology, Merkel cell carcinoma, business.industry, medicine, Cancer research, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business
Published
2020
Full Text
View/download PDF

7. 18F-FLT PET changes during radio - therapy combined with cetuximab in head and neck squamous cell carcinoma patients

Author

J.H.A.M. Kaanders, Jan Bussink, C.M.L. van Herpen, Wim J.G. Oyen, Bianca A.W. Hoeben, Esther G.C. Troost, Radiotherapie, RS: GROW - Oncology, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Male, Oncology, medicine.medical_treatment, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, cetuximab, Medicine, Epidermal growth factor receptor, Cetuximab, biology, Chemoradiotherapy, General Medicine, Middle Aged, Treatment Outcome, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Immunohistochemistry, Female, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Antibodies, Monoclonal, Humanized, Sensitivity and Specificity, 03 medical and health sciences, Internal medicine, [F-18] fluorothymidine PET, Humans, Radiology, Nuclear Medicine and imaging, Proliferation Marker, radiotherapy, Aged, Squamous Cell Carcinoma of Head and Neck, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Head and neck cancer, Reproducibility of Results, medicine.disease, Head and neck squamous-cell carcinoma, Dideoxynucleosides, digestive system diseases, Radiation therapy, Positron-Emission Tomography, Concomitant, biology.protein, early response monitoring, head and neck cancer, Radiopharmaceuticals, Radiotherapy, Conformal, business
Abstract

SummaryAim: Early treatment response of head and neck cancer to radiotherapy concomitant with cetuximab was monitored by repetitive PET imaging with the proliferation tracer 18F-FLT. Patients, methods: Five head and neck cancer patients, treated with radiotherapy and concomitant cetuximab following cetuximab induction, received four 18F-FLT PET-CT scans before and during treatment. Changes in SUVpeak, SUVmean and CT- and PET-segmented gross tumour volumes were evaluated, as were correlations with immu- nohistochemical staining for Epidermal Growth Factor Receptor (EGFR) and Ki-67 (proliferation marker) in pre-treatment tumour biopsies. Results: 18F-FLT PET measured tumor responses to the induction dose of ce- tuximab varied from 43% SUVpeak decrease to 47% increase. After start of radiotherapy 18F-FLT PET parameters decreased significantly in all patients. No associations were found between PET parameters and EGFR or Ki-67 expression levels. Conclusion: Proliferation of head and neck carcinomas shows a varying response to cetuximab induction, but consistently decreases after addition of radiotherapy.

Published
2014
Full Text
View/download PDF

8. OC-0289: Cancer of the nasal vestibule: excellent outcomes with sole image guided brachytherapy

Author

Michal D. Czerwinski, Cornelia G. Verhoef, Djoeri Lipman, R. Van Leeuwen, Ellen M. Zwijnenburg, R.P. Takes, and J.H.A.M. Kaanders

Subjects
medicine.medical_specialty, medicine.anatomical_structure, Oncology, business.industry, Image guided brachytherapy, medicine, Cancer, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, Nasal vestibule, business, medicine.disease
Published
2018
Full Text
View/download PDF

9. SP-0532: Molecular imaging of proliferation and hypoxia

Author

Jan Bussink, J.H.A.M. Kaanders, Bianca A.W. Hoeben, and Wim Oyen

Subjects
stomatognathic diseases, Oncology, Chemistry, Radiology Nuclear Medicine and imaging, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Hypoxia (medical), medicine.symptom, Molecular imaging, Cell biology
Published
2015
Full Text
View/download PDF

10. From anatomical to biological target volumes: the role of PET in radiation treatment planning

Author

J.H.A.M. Kaanders, Dominic A.X. Schinagl, and Wim J.G. Oyen

Subjects
medicine.medical_specialty, medicine.medical_treatment, Radiation Tolerance, Sensitivity and Specificity, Patient Care Planning, Article, Fluorodeoxyglucose F18, Neoplasms, Image Interpretation, Computer-Assisted, Radiation oncology, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Misonidazole, Radiation treatment planning, Observer Variation, Clinical Trials as Topic, Radiotherapy, Radiological and Ultrasound Technology, medicine.diagnostic_test, business.industry, fungi, Reproducibility of Results, food and beverages, Magnetic resonance imaging, General Medicine, target volume, Magnetic Resonance Imaging, Cell Hypoxia, Tumor Burden, Radiation therapy, PET, Oncology, Biological target, Positron emission tomography, Positron-Emission Tomography, Radiology, Radiopharmaceuticals, Molecular imaging, Tomography, X-Ray Computed, business, Nuclear medicine, Preclinical imaging
Abstract

Progress in radiation oncology requires a re-evaluation of the methods of target volume delineation beyond anatomical localization. New molecular imaging techniques for tumour visualisation such as positron emission tomography (PET) provide insight into tumour characteristics and can be complementary to the anatomical data of computed tomography or magnetic resonance imaging. In this review, three issues are discussed: First, can PET identify a tumour more accurately? Second, can biological tumour characteristics be visualised? Third, can intratumoural heterogeneity of these characteristics be identified?

Published
2006
Full Text
View/download PDF

11. EP-1099: Re-irradiation for head and neck tumors: efficacy versus late toxicity in 137 patients

Author

S. Van den Bosch, G. van den Broek, Ellen M. Zwijnenburg, Wouter Bots, Tim Dijkema, Geert O. Janssens, Willem L. J. Weijs, L.C. Verhoef, and J.H.A.M. Kaanders

Subjects
Late toxicity, Re-Irradiation, medicine.medical_specialty, Oncology, Radiology Nuclear Medicine and imaging, business.industry, Head and neck tumors, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business
Published
2016
Full Text
View/download PDF

12. PO-0943: Dutch national head and neck plan comparison significantly improved treatment planning quality

Author

J.H.A.M. Kaanders, Luc J Bos, C.P.J. Raaijmakers, Patricia Doornaert, Marion Essers, C.H.J. Terhaard, and Wilko F.A.R. Verbakel

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, Plan (drawing), Hematology, Audiology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Oncology, Radiology Nuclear Medicine and imaging, 030220 oncology & carcinogenesis, Medicine, Radiology, Nuclear Medicine and imaging, Quality (business), Operations management, business, Head and neck, Radiation treatment planning, media_common
Published
2016
Full Text
View/download PDF

13. SP-0061: Head and neck cancer: FDG imaging and beyond

Author

Jan Bussink, J.H.A.M. Kaanders, Wim J.G. Oyen, Bianca A.W. Hoeben, and E.G.C. Troost

Subjects
medicine.medical_specialty, Oncology, business.industry, Radiology Nuclear Medicine and imaging, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Radiology, Hematology, business, medicine.disease
Published
2015
Full Text
View/download PDF

14. OC-0534: An RCT on the value of postoperative accelerated radiotherapy in squamous cell head and neck cancer: final results

Author

Johannes A. Langendijk, P. van den Ende, Patricia Doornaert, S.B. Oei, H. van Tinteren, J.H.A.M. Kaanders, Sandra Nuyts, and C.R. Leemans

Subjects
Oncology, medicine.medical_specialty, business.industry, Cell, Head and neck cancer, Hematology, medicine.disease, law.invention, medicine.anatomical_structure, Randomized controlled trial, law, Radiology Nuclear Medicine and imaging, Internal medicine, Accelerated radiotherapy, medicine, Radiology, Nuclear Medicine and imaging, business, Value (mathematics)
Published
2015
Full Text
View/download PDF

15. PD-0049: Quality of life after radiotherapy for advanced laryngeal cancer: results of the phase III ARCON trial

Author

R.P. Takes, J.H.A.M. Kaanders, Johannes A. Langendijk, Geert O. Janssens, M.A. De Jong, P. van den Ende, Paul N. Span, C.H.J. Terhaard, and Patricia Doornaert

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Hematology, medicine.disease, Radiation therapy, Quality of life, Radiology Nuclear Medicine and imaging, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2015
Full Text
View/download PDF

16. OC-008: POPART vs CPORT in squamous cell head and neck cancer: Results of a multicenter randomised study of the Dutch head and neck Study Group

Author

Fred R. Burlage, Sandra Nuyts, S.B. Oei, H. van Tinteren, Patricia Doornaert, J.H.A.M. Kaanders, Ronald B. Keus, H. Langendijk, C.R. Leemans, P. van den Ende, and C.H.J. Terhaard

Subjects
medicine.medical_specialty, Oncology, business.industry, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, Head and neck, business, Surgery
Published
2015
Full Text
View/download PDF

17. SP-0425: Molecular imaging as biomarker in future clinical trials: The proof of the pudding is in the eating

Author

Wim J.G. Oyen, J.H.A.M. Kaanders, Bianca A.W. Hoeben, Jan Bussink, and E.G.C. Troost

Subjects
Oncology, Pathology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, Radiation therapy, Clinical trial, Radiology Nuclear Medicine and imaging, Internal medicine, medicine, Biomarker (medicine), Radiology, Nuclear Medicine and imaging, Molecular imaging, business
Published
2013
Full Text
View/download PDF

18. Ototoxicity in locally advanced head and neck cancer (LAHNC) patients (pts) treated with induction chemotherapy (IC) followed by cisplatin-based chemoradiotherapy (CRT)

Author

Ad F. M. Snik, C.M.L. van Herpen, J.P. de Boer, W.T.A. van der Graaf, Hans Gelderblom, Chantal Driessen, J.H.A.M. Kaanders, Joop M. Leijendeckers, and C. van Opstal

Subjects
Oncology, Cisplatin, medicine.medical_specialty, business.industry, Head and neck cancer, Locally advanced, Induction chemotherapy, Hematology, medicine.disease, Ototoxicity, Internal medicine, medicine, business, Chemoradiotherapy, medicine.drug
Published
2016
Full Text
View/download PDF

19. PD-0048: Patterns of recurrence in electively irradiated lymph nodes after definitive IMRT for head and neck cancer

Author

Ellen M. Zwijnenburg, J.H.A.M. Kaanders, Geert O. Janssens, S. Van den Bosch, L.C. Verhoef, and Tim Dijkema

Subjects
medicine.medical_specialty, Oncology, Radiology Nuclear Medicine and imaging, business.industry, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, Lymph, business, medicine.disease
Published
2015
Full Text
View/download PDF

21. PD-0093: CT-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial

Author

M. de Jong, Paul N. Span, Patricia Doornaert, Henk P. Bijl, Geert O. Janssens, P.I.E.T. van den Ende, G. van den Broek, J.H.A.M. Kaanders, and C.H.J. Terhaard

Subjects
Oncology, medicine.medical_specialty, business.industry, Cancer, Hematology, medicine.disease, Outcome (game theory), Radiology Nuclear Medicine and imaging, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Tumour volume, business
Published
2013
Full Text
View/download PDF

22. PO-0665: Inhibition of DNA repair by Dasatinib is located in pSFK expressing tumor areas in head and neck xenografts

Author

Mari Iida, Jan Bussink, A.J. van der Kogel, Deric L. Wheeler, Paul N. Span, J.H.A.M. Kaanders, and Hanneke Stegeman

Subjects
Dasatinib, Pathology, medicine.medical_specialty, Oncology, DNA repair, business.industry, Radiology Nuclear Medicine and imaging, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Head and neck, business, medicine.drug
Published
2013
Full Text
View/download PDF

24. EP-1589 EXPRESSION OF E-CADHERIN AND VIMENTIN ON METASTASIS FORMATION IN HEAD AND NECK CANCER

Author

Paul N. Span, A.J. van der Kogel, I.J. Hoogsteen, J.H.A.M. Kaanders, Monique M. Nijkamp, and Jan Bussink

Subjects
Oncology, medicine.medical_specialty, biology, Cadherin, business.industry, Metastasis formation, Head and neck cancer, Vimentin, Hematology, medicine.disease, Internal medicine, medicine, biology.protein, Cancer research, Radiology, Nuclear Medicine and imaging, business
Published
2012
Full Text
View/download PDF

25. SP-0018 BIOLOGICAL ADAPTATION STRATEGIES

Author

Jelle O. Barentsz, Wim J.G. Oyen, J.H.A.M. Kaanders, E.C.G. Troost, Jan Bussink, and Bianca A.W. Hoeben

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology, Computational biology, Biological adaptation, Biology
Published
2012
Full Text
View/download PDF

26. 14 PREDICTIVE VALUE OF CAIX EXPRESSION AND STAINING PATTERN IN PATIENTS WITH LARYNGEAL CANCER TREATED IN THE PHASE III RANDOMISED ARCON TRIAL

Author

P. van den Ende, Johannes A. Langendijk, Saskia E. Rademakers, A.J. van der Kogel, P.F.J.W. Rijken, C.H.J. Terhaard, Jan Bussink, J.H.A.M. Kaanders, I.J. Hoogsteen, and Patricia Doornaert

Subjects
Oncology, medicine.medical_specialty, Pathology, business.industry, Cancer, Hematology, medicine.disease, Predictive value, Staining, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, In patient, business
Published
2012
Full Text
View/download PDF

27. PREDICTIVE VALUE OF PIMONIDAZOLE FOR ARCON THERAPY IN ADVANCED HEAD AND NECK CANCER

Author

R. de Bree, Saskia E. Rademakers, Jan Bussink, A.J. van der Kogel, Patricia Doornaert, I.J. Hoogsteen, J.H.A.M. Kaanders, and H.A.M. Marres

Subjects
medicine.medical_specialty, Oncology, business.industry, Head and neck cancer, Medicine, Pimonidazole, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, medicine.disease, Predictive value
Published
2011
Full Text
View/download PDF

28. PO-0943: Systematic 18F-FDG PET and immunohistochemistry analysis for differentiation between head and neck tumors

Author

Jan Bussink, A.J. van der Kogel, Maud H.W. Starmans, L.J. Dubois, Ralph T.H. Leijenaar, P.N. Boutros, J.H.A.M. Kaanders, and Bianca A.W. Hoeben

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Head and neck tumors, Medicine, Immunohistochemistry, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine, 18f fdg pet
Published
2014
Full Text
View/download PDF

30. The tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of molecular markers

Author

Karien I.E.M. Wijffels, I.J. Hoosteen, A.J. van der Kogel, J.H.A.M. Kaanders, H.A.M. Marres, and F.J.A. van den Hoogen

Subjects
Oncology, medicine.medical_specialty, Tumor microenvironment, business.industry, Cell, Hematology, Predictive value, medicine.anatomical_structure, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Clinical significance, Head and neck, business
Published
2007
Full Text
View/download PDF

31. Positron emission tomography in head and neck cancer

Author

Henri A. M. Marres, Matthias A.W. Merkx, J.H.A.M. Kaanders, F. VandenHoogen, E.G.C. Troost, Dominic A.X. Schinagl, Wim J.G. Oyen, Wouter V. Vogel, and Bart M Wensing

Subjects
Oncology, medicine.diagnostic_test, business.industry, Positron emission tomography, Head and neck cancer, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine, medicine.disease
Published
2007
Full Text
View/download PDF

32. 107 Comparison of 18F-MISO autoradiography with immunohistochemistry after modification of hypoxia in human glioma and squamous cell xenografts

Author

A.J. van der Kogel, Otto C. Boerman, E.G.C. Troost, Jan Bussink, Peter Laverman, Marielle E.P. Philippens, Jasper Lok, and J.H.A.M. Kaanders

Subjects
Pathology, medicine.medical_specialty, Human glioma, business.industry, Cell, Hematology, Hypoxia (medical), medicine.anatomical_structure, Oncology, medicine, Immunohistochemistry, Radiology, Nuclear Medicine and imaging, medicine.symptom, business
Published
2006
Full Text
View/download PDF

33. PP088-SUN SWALLOWING THERAPY DOES NOT ACCELERATE RETURN TO NORMAL FOOD INTAKE AFTER RADIOTHERAPY, BUT INTENSIVE DIETARY COUNSELING MAY LIMIT TUBE FEEDING AND PREVENT EXCESSIVE WEIGHT LOSS

Author

Geert J. A. Wanten, M.G.A. van den Berg, M.A.W. Merkx, Johanna G. Kalf, J.H.A.M. Kaanders, and Joost P.H. Drenth

Subjects
medicine.medical_specialty, Food intake, Nutrition and Dietetics, business.industry, medicine.medical_treatment, Critical Care and Intensive Care Medicine, Surgery, Radiation therapy, Dietary counseling, Anesthesia, Medicine, Swallowing therapy, Tube (fluid conveyance), Excessive weight loss, business
Published
2013
Full Text
View/download PDF

35. OC-0152 IMAGING OF EGFR WITH USPECT IN HEAD AND NECK CANCER XENOGRAFTS WITH 111-IN-LABELED CETUXIMAB-F(ABÍ)2

Author

O.C. Boerman, Jan Bussink, Hanneke Stegeman, Wim J.G. Oyen, Johannes H.A.M. Kaanders, L.K. van Dijk, J.H.A.M. Kaanders, and Gerben Franssen

Subjects
Oncology, medicine.medical_specialty, Cetuximab, business.industry, Internal medicine, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, medicine.drug
Published
2012
Full Text
View/download PDF

36. PD-0444 18F-FLT PET; AN EARLY PREDICTOR OF OUTCOME AFTER (CHEMO)RADIOTHERAPY IN HEAD AND NECK CANCER

Author

E.G.C. Troost, C.M.L. van Herpen, Bianca A.W. Hoeben, Wim J.G. Oyen, Jan Bussink, and J.H.A.M. Kaanders

Subjects
Chemo-radiotherapy, medicine.medical_specialty, business.industry, Potential risk, Head and neck cancer, Normal tissue, Hematology, medicine.disease, Oncology, Planning study, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, business
Abstract

Conclusions: IMRT gives the opportunity to deliver highly conformal irradiation but also implies a potential risk to miss a part of the target. In this study, almost half of all LRF appeared in the CTV HD volume. When exploring margin extension of the CTV-T HD volume it was possible to include 11% more PO’s by adding 5 mm extra margin. This does not implicate that increasing HD volume alone would reduce failure rate. The question of increasing volume and/or dose and the consequences for target and normal tissue will be further analyzed in a planning study.

Published
2012
Full Text
View/download PDF

38. OC-0217 IMPACT OF ARCON ON OUTCOME IN PATIENTS WITH LARYNGEAL CANCER AND PRE-IRRADIATION ANEMIA: A PHASE III TRIAL ANALYSIS

Author

Geert O. Janssens, Paul N. Span, Alim Chin, J.H.A.M. Kaanders, Henk P. Bijl, A.J. van der Kogel, P. van den Ende, C.H.J. Terhaard, and Patricia Doornaert

Subjects
Pre irradiation, medicine.medical_specialty, business.industry, Anemia, Cancer, Hematology, medicine.disease, Surgery, Oncology, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, In patient, business
Published
2012
Full Text
View/download PDF

40. OC-0153 EGFR-INHIBITION AND RADIOTHERAPY IN HEAD AND NECK CANCER XENOGRAFTS: HYPOXIA, PROLIFERATION AND TUMOR GROWTH DELAY

Author

Mari Iida, Deric L. Wheeler, Paul N. Span, Hanneke Stegeman, A.J. van der Kogel, Jan Bussink, and J.H.A.M. Kaanders

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Egfr inhibition, Head and neck cancer, Hematology, Hypoxia (medical), medicine.disease, Radiation therapy, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Tumor growth, medicine.symptom, business
Published
2012
Full Text
View/download PDF

41. PO-0942 EXPRESSION OF THE EGFR/HER2/PAKT PATHWAY IN VITRO AND IN VIVO IS AFFECTED BY HYPOXIA IN HUMAN HEAD AND NECK CANCER

Author

Jan Bussink, Paul N. Span, Mari Iida, A.J. van der Kogel, J.H.A.M. Kaanders, Hanneke Stegeman, and Deric L. Wheeler

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, Hypoxia (medical), In vitro, In vivo, Internal medicine, medicine, Cancer research, Radiology, Nuclear Medicine and imaging, medicine.symptom, business
Published
2012
Full Text
View/download PDF

42. OC-0150 PREDICTIVE VALUE OF CAIX EXPRESSION AND STAINING PATTERN IN PATIENTS TREATED IN THE PHASE III RANDOMISED ARCON TRIAL

Author

P.F.J.W. Rijken, Patricia Doornaert, Johannes A. Langendijk, I.J. Hoogsteen, J.H.A.M. Kaanders, A.J. van der Kogel, Saskia E. Rademakers, P. van den Ende, C.H.J. Terhaard, and Jan Bussink

Subjects
medicine.medical_specialty, Oncology, business.industry, Internal medicine, Phase (matter), Medicine, Radiology, Nuclear Medicine and imaging, In patient, Hematology, business, Predictive value, Gastroenterology, Staining
Published
2012
Full Text
View/download PDF

43. 44 INVOLVEMENT OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN LARYNGEAL CANCER PATIENTS TREATED WITH HYPOXIA MODIFICATION AS AN ADDITIVE TO ACCELERATED RADIOTHERAPY

Author

Johannes A. Langendijk, J.H.A.M. Kaanders, P. van den Ende, I.J. Hoogsteen, C.H.J. Terhaard, Jan Bussink, Paul N. Span, Monique M. Nijkamp, A.J. van der Kogel, Patricia Doornaert, and Alim Chin

Subjects
Oncology, medicine.medical_specialty, biology, business.industry, Cancer, Hematology, Hypoxia (medical), medicine.disease, Internal medicine, Accelerated radiotherapy, medicine, biology.protein, Radiology, Nuclear Medicine and imaging, Epidermal growth factor receptor, medicine.symptom, business
Published
2012
Full Text
View/download PDF

44. 61 EFFECTS OF EGFR-INHIBITION AND RADIOTHERAPY ON HYPOXIA, PROLIFERATION AND TUMOR GROWTH DELAY IN HUMAN TUMOR XENOGRAFTS

Author

A.J. van der Kogel, Deric L. Wheeler, Jan Bussink, Paul N. Span, J.H.A.M. Kaanders, and Hanneke Stegeman

Subjects
business.industry, Egfr inhibition, medicine.medical_treatment, Hematology, Hypoxia (medical), Human tumor, Radiation therapy, Oncology, Cancer research, Medicine, Radiology, Nuclear Medicine and imaging, Tumor growth, medicine.symptom, business
Published
2012
Full Text
View/download PDF

45. 132 oral EXPRESSION OF THE EPIDERMAL GROWTH FACTOR PREDICTS THE EFFECT OF HYPOXIA MODIFICATION AS AN ADDITIVE TO ACCELERATED RADIOTHERAPY OF LARYNGEAL CANCER IN A RANDOMIZED TRIAL

Author

Paul N. Span, Jan Bussink, Alim Chin, H. Langendijk, Patricia Doornaert, Monique M. Nijkamp, J.H.A.M. Kaanders, I.J. Hoogsteen, P. van den Ende, C.H.J. Terhaard, and A.J. van der Kogel

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, Hypoxia (medical), law.invention, Randomized controlled trial, law, Epidermal growth factor, Internal medicine, Accelerated radiotherapy, medicine, Radiology, Nuclear Medicine and imaging, medicine.symptom, business
Published
2011
Full Text
View/download PDF

48. ARCON FOR T2-T4 LARYNGEAL CANCER: RESULTS OF A PHASE 111 RANDOMIZED TRIAL

Author

P. van den Ende, R.P. Takes, C.H.J. Terhaard, Alim Chin, Patricia Doornaert, H.P. Bij, R. de Bree, Paul N. Span, Geert O. Janssens, and J.H.A.M. Kaanders

Subjects
Oncology, medicine.medical_specialty, business.industry, Cancer, Hematology, medicine.disease, law.invention, Randomized controlled trial, law, Phase (matter), Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, business
Published
2011
Full Text
View/download PDF

49. 10 oral: PET-Imaging of Hypoxia Using 89ZR-Labeled CG250-F(AB’)2

Author

Wim J.G. Oyen, Bianca A.W. Hoeben, Egbert Oosterwijk, Jan Bussink, Peter Laverman, J.H.A.M. Kaanders, and Otto C. Boerman

Subjects
Pathology, medicine.medical_specialty, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Pet imaging, Hypoxia (medical), medicine.symptom, business
Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results